Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Immuneering presented the design and methodology of its ongoing pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer in a trial-in-progress poster at ESMO 2026. The global, randomized trial tests overall survival as its primary endpoint versus standard-of-care gemcitabine/nab-paclitaxel, with dosing underway since June 2026.
Key figures
- Drug Name
- atebimetinib
- Phase Of Trial
- Phase 3
- Trial
- MAPKeeper 301 (NCT07562152)
- Phase2a dcr pct
- 82%
- Phase2a orr pct
- 36%
- Phase2a patients
- 55
- Phase2a median os months
- 17.3
- Phase2a median pfs months
- 8.3
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.